Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 8Recruiting 7Active not recruiting 3Unknown 2Not yet recruiting 2Withdrawn 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Conditions

Neoplasms 2Wounds and Injuries 1Trauma, Nervous System 1Stress Disorders, Post-Traumatic 1Depressive Disorder, Major 1Depression 1

Interventions

Cisplatin 512Radiotherapy 376Cyclophosphamide 361Carboplatin 354Capecitabine 341Oxaliplatin 331Paclitaxel 328Gemcitabine 318Docetaxel 314Fluorouracil 288Drug Therapy 271apatinib 245Bevacizumab 243camrelizumab 217Etoposide 200Irinotecan 182Doxorubicin 180Leucovorin 160Dexamethasone 160pembrolizumab 150sintilimab 143Neoadjuvant Therapy 142anlotinib 139Pemetrexed 138Cytarabine 138Blood Specimen Collection 138Surgical Procedures, Operative 130toripalimab 128Radiosurgery 127S 1 (combination) 124

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Psilocybin × Clear all
NCT05042466 2022-11-16

NWTTPS

NWTraumatherapies

Phase 1 Unknown
30 enrolled

Depression, Neoplasms, Stress Disorders, Post-Traumatic, Wounds and Injuries, Trauma, Nervous System

NCT04593563 2021-10-15

The Safety and Efficacy of Psilocybin in Cancer Patients With Major Depressive Disorder

Maryland Oncology Hematology, PA

Phase 2 Unknown
30 enrolled

Depressive Disorder, Major, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡